Carna BiosciencesCarna Biosciences, Inc.4572東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP

Carna Biosciences FY ending Dec 2019 results

About 66% of Carna Biosciences's sales come from Drug discovery business, with Drug discovery support business making up much of the rest.

Out of every ¥100 of sales, about ¥31 is left as operating profit.

Where the money goes

For every ¥100 Carna Biosciences sells, how much goes where, and how much is kept.

FY ending Dec 2019

Margin funnel (derived from reported values)Gross margin 93.5% → Operating margin 30.5% → Net margin 25.8%

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2019

Drug discovery business¥2.13B
66%
Op. margin 27.1%Industry: Biotech & Regenerative Medicine
Drug discovery support business¥1.08B
34%
Op. margin 37.1%Industry: CRO & Clinical Testing

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第21期(2023/01/01－2023/12/31)
ID S100T2Q72024-03-27Open
EDINET (FSA Japan)
有価証券報告書－第19期(令和3年1月1日－令和3年12月31日)
ID S100NPCS2022-03-25Open
EDINET (FSA Japan)
有価証券報告書－第18期(令和2年1月1日－令和2年12月31日)
ID S100KZV22021-03-26Open

Extracted from XBRL: 39 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.